heart failure

Lexicon gets FDA approval for Inpefa to treat heart failure
Lexicon gets FDA approval for Inpefa to treat heart failure
Pharmaceutical Technology
Lexicon Pharmaceuticals
FDA
Inpefa
heart failure
Flag link:
Farxiga’s approval for expanded use highlights potential to differentiate in HF space
Farxiga’s approval for expanded use highlights potential to differentiate in HF space
Clinical Trials Arena
AstraZeneca
Farxiga
heart failure
Flag link:
Boehringer Ingelheim and Eli Lilly's Jardiance gets big lift from heart failure indications
Boehringer Ingelheim and Eli Lilly's Jardiance gets big lift from heart failure indications
Fierce Pharma
Boehringer Ingelheim
Eli Lilly
Jardiance
heart failure
Flag link:
FDA turns down Cytokinetics’ once-promising heart failure drug omecamtiv
FDA turns down Cytokinetics’ once-promising heart failure drug omecamtiv
Fierce Pharma
Cytokinetics
heart failure
FDA
complete response letter
Omecamtiv Mecarbil
Flag link:
Novo sows the seeds for a new heart failure approach
Novo sows the seeds for a new heart failure approach
EP Vantage
Novo Nordisk
HS-001
cell therapy
heart failure
Flag link:
Heart hope for Heartseed/Novo Nordisk HS-001 cell therapy
Heart hope for Heartseed/Novo Nordisk HS-001 cell therapy
Pharmaphorum
Novo Nordisk
Heartseed
clinical trials
HS-001
cell therapy
heart failure
Flag link:
AstraZeneca's Forxiga nabs expanded heart failure approval in Europe
AstraZeneca's Forxiga nabs expanded heart failure approval in Europe
Fierce Pharma
AstraZeneca
Europe
Forxiga
heart failure
Flag link:
FDA advisers nix Cytokinetics' heart failure med, rejecting argument for subgroup use
FDA advisers nix Cytokinetics' heart failure med, rejecting argument for subgroup use
Fierce Biotech
FDA
Cytokinetics
heart failure
Omecamtiv Mecarbil
Flag link:
Ahead of adcomm, FDA raises uncertainties on benefit-risk profile of Cytokinetics' potential heart drug
Ahead of adcomm, FDA raises uncertainties on benefit-risk profile of Cytokinetics' potential heart drug
Endpoints
FDA
Cytokinetics
heart failure
Omecamtiv Mecarbil
Flag link:
Abbott’s HeartMate 3 extends life by 5 years for advanced heart failure patients
Abbott’s HeartMate 3 extends life by 5 years for advanced heart failure patients
MedCity News
Abbott Labs
Medtech
devices
HeartMate 3
advanced heart failure
heart failure
Flag link:
Bayer’s BlueRock inks cardiovascular cell therapy delivery deal
Bayer’s BlueRock inks cardiovascular cell therapy delivery deal
Fierce Pharma
Bayer
BlueRock Therapeutics
heart failure
cell therapy
BioCardia
Flag link:
Abbott Gets to the Heart of Extending Life-Expectancy with HeartMate 3 Data
Abbott Gets to the Heart of Extending Life-Expectancy with HeartMate 3 Data
Medical Devices and Diagnostics Industry
Abbott Labs
devices
Medtech
heart failure
HeartMate 3
Flag link:
AstraZeneca’s Farxiga reduces CV mortality risk in Phase III trials
AstraZeneca’s Farxiga reduces CV mortality risk in Phase III trials
Clinical Trials Arena
AstraZeneca
Farxiga
clinical trials
heart failure
Flag link:
Cytokinetics aims to become the Vertex of cardiovascular disease
Cytokinetics aims to become the Vertex of cardiovascular disease
EP Vantage
Cytokinetics
Amgen
heart failure
Omecamtiv Mecarbil
cardiovascular disease
Flag link:
Will third time be the charm? Lexicon finally refiles SGLT2 drug for heart failure
Will third time be the charm? Lexicon finally refiles SGLT2 drug for heart failure
Endpoints
Lexicon Pharmaceuticals
sotagliflozin
heart failure
FDA
Flag link:
AZ bites back at rivals with new Farxiga data in heart failure
AZ bites back at rivals with new Farxiga data in heart failure
Pharmaforum
AstraZeneca
Farxiga
heart failure
clinical trials
Flag link:
CEO of cardiology startup declares that its tech could potentially cure heart failure
CEO of cardiology startup declares that its tech could potentially cure heart failure
MedCity News
Ceryx
cardiology
startups
heart failure
Medtech
devices
Cysoni
Flag link:
ACC: Lexicon hopes sotagliflozin cardio data will set its drug apart from SGLT2 rivals
ACC: Lexicon hopes sotagliflozin cardio data will set its drug apart from SGLT2 rivals
Fierce Pharma
Lexicon Pharmaceuticals
ACC
diabetes
sotagliflozin
type 2 diabetes
heart failure
Flag link:
Eli Lilly, Boehringer Ingelheim's Jardiance turns up heat on AstraZeneca's Farxiga with broad EU heart failure approval
Eli Lilly, Boehringer Ingelheim's Jardiance turns up heat on AstraZeneca's Farxiga with broad EU heart failure approval
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
heart failure
Europe
AstraZeneca
Farxiga
Flag link:
Eli Lilly, Boehringer Ingelheim's Jardiance clinches heart failure edge with FDA nod for wider label
Eli Lilly, Boehringer Ingelheim's Jardiance clinches heart failure edge with FDA nod for wider label
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
heart failure
FDA
Flag link:

Pages